Item 8.01 Other Events. On December 21, 2022, NeuroOne Medical Technologies Corporation (the “Company”) entered into a Capital on Demand™ Sales Agreement (the “Sales Agreement”) with JonesTrading Institutional Services LLC (“JonesTrading”) pursuant to which the Company may sell from time to time shares of its common stock, par value $0.001 (the “Shares”) through any method permitted that is deemed…
Filed Jun 12, 2026Accepted Jun 12, 2026, 4:45 PM EDTCIK 1500198Accession 0001213900-26-068327
NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery, basivertebral nerve ablation and spinal cord stimulation programs. For more information, visit nmtc1.com.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On December 21, 2022, NeuroOne
Medical Technologies Corporation (the “Company”) entered into a Capital on Demand™ Sales Agreement (the “Sales
Agreement”) with JonesTrading Institutional Services LLC (“JonesTrading”) pursuant to which the Company may sell from
time to time shares of its common stock, par value $0.001 (the “Shares”) through any method permitted that is deemed an “at
the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, under which JonesTrading will act
as sales agent (the “ATM Program”). On June 12, 2026, the Company filed an updated Prospectus Supplement (the “Prospectus”)
for the offer and sale of up to $13.4 million of Shares through JonesTrading pursuant to the Sales Agreement.
Honigman LLP, counsel to the
Company, has issued an opinion relating to the Shares. A copy of such legal opinion is attached as Exhibit 5.1 hereto.
The Shares will be sold pursuant
to the Registration Statement, and offerings of the Shares will be made only by means of the Prospectus. This Current Report on Form 8-K
shall not constitute an offer to sell or solicitation of an offer to buy these securities, nor shall there be any sale of these securities
in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law
of such state or jurisdiction
